IPO registrations (S-1, F-1) · Registrants
Cascadian Therapeutics, Inc.
- SEC CIK
- 1412067 · filings on EDGAR ↗
- Name on the registration
- Oncothyreon Inc.
- Former names
- Oncothyreon Inc. (2007–2016); Biomira CORP (2007–2007)
- Registration
- Form S-1, first filed 2010-07-14, last 2011-03-14; 2 initial registrations, 2 amendments
- Outcome
- Declared effective 2010-07-28
- Industry (SIC)
- Services-Commercial Physical & Biological Research 8731
- Incorporated in
- DE
- Business address
- 3101 WESTERN AVE., SUITE 600, Seattle, WA 98121
- EIN
- 26-0868560
- EDGAR entity type
- operating
- Insiders and CEO pay
- Cascadian Therapeutics, Inc. on the corporate pages
Offering terms
- Shares offered
- 7,425,017
- Listing
- Nasdaq under the symbol ONTY
- Lead underwriters
- Miscellaneous (130,000 shares)
- Syndicate
- Printing costs (25,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CASCADIAN THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: CASCADIAN THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Oncothyreon Inc. EXACT (CIK (EXACT))
- SEC filer: Cascadian Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 12
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2010-07-14 | S-1 | S-1 (registration) | Oncothyreon Inc. | 0000950123-10-065452 ↗ |
| 2010-07-28 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-10-002279 ↗ |
| 2010-10-04 | S-1 | S-1 (registration) | Oncothyreon Inc. | 0000950123-10-091166 ↗ |
| 2010-10-08 | S-1/A | S-1/A (amendment) | Oncothyreon Inc. | 0000950123-10-092372 ↗ |
| 2010-10-12 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-10-002910 ↗ |
| 2011-03-14 | S-1/A | S-1/A (amendment) | Oncothyreon Inc. | 0000950123-11-025253 ↗ |
| 2011-03-22 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-11-000734 ↗ |
| 2011-04-08 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-11-000968 ↗ |
| 2011-04-08 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-11-000969 ↗ |
| 2011-04-08 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-11-000970 ↗ |
| 2012-01-10 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-12-000159 ↗ |
| 2012-03-21 | EFFECT | EFFECT (declared effective) | Oncothyreon Inc. | 9999999995-12-000788 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2011-03-14 | S-1/A | registration statement | 7,425,017 | - | Nasdaq ONTY | 2 | primary document; shares headline, underwriting table 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Blair S. Robert | Director | 2 | 2007 | ||
| Christianson Gary | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 20 | 2007–2018 | |
| Jackson Richard L. | Director | 23 | 2007–2017 | ||
| KIRKMAN ROBERT L | Director,Officer | President and CEO; PRESIDENT AND CEO; President & CEO; President/CEO | 14 | 2007–2015 | |
| Kirkpatrick Lynn | Officer | Chief Scientific Officer | 3 | 2007–2008 | |
| STOUGHTON W VICKERY | Director | 18 | 2007–2014 | ||
| Taylor Edward A. | Officer | CFO, VP Fin & Admin, Sec; CFO, VP Fin Admin, Sec | 4 | 2007–2008 | |
| HENNEY CHRISTOPHER S | Director; Director,Officer | Interim CEO and President | 32 | 2007–2018 | |
| Welsh Michael C. | Director | 2 | 2007 | ||
| Burley Stephen | Director | 1 | 2008 | ||
| SPIEGELMAN DANIEL K | Director | 25 | 2008–2018 | ||
| Karan Shashi | Officer | Corporate Controller | 7 | 2009–2010 | |
| WILLIAMS DOUGLAS E | Director | 9 | 2009–2013 | ||
| EASTLAND JULIA MARIE | Officer | CFO AND VP CORP DEVELOPMENT; CFO & CBO; CFO & VP Corp. Dev.; CFO & VP, Corp Development; CFO & VP, Corp. Development; CFO & VP, CORP. DEVELOPMENT | 15 | 2010–2018 | |
| ACM Capital Partners, LLC | TenPercentOwner | 5 | 2011 | ||
| Ayer Capital Management, LP | TenPercentOwner | 6 | 2011 | ||
| Ayer Capital Partners, LLC | TenPercentOwner | 5 | 2011 | ||
| Venkatesan Jay | Officer; TenPercentOwner | EVP and General Manager | 11 | 2011–2014 | |
| HAUSMAN DIANA | Officer | Chief Medical Officer | 7 | 2012–2015 | |
| PETERSON SCOTT ROBERT | Officer | Chief Scientific Officer | 12 | 2012–2018 | |
| BIOTECHNOLOGY VALUE FUND II LP | Other; TenPercentOwner | 11 | 2013–2016 | ||
| BIOTECHNOLOGY VALUE FUND L P | Other; TenPercentOwner | 11 | 2013–2016 | ||
| BVF INC/IL | Other; TenPercentOwner | 11 | 2013–2016 | ||
| BVF PARTNERS L P/IL | Other; TenPercentOwner | 11 | 2013–2016 | ||
| INVESTMENT 10 LLC | Other | 1 | 2013 | ||
| LAMPERT MARK N | Director,TenPercentOwner; Other; TenPercentOwner | 11 | 2013–2016 | ||
| LOVE TED W | Director | 13 | 2013–2018 | ||
| James Steven P | Director | 10 | 2015–2018 | ||
| Biotechnology Value Trading Fund OS LP | Other; TenPercentOwner | 2 | 2015–2016 | ||
| BVF Partners OS Ltd. | Other; TenPercentOwner | 2 | 2015–2016 | ||
| Fyfe Gwen A. | Director | 6 | 2016–2018 | ||
| Myers Scott Dunseth | Director,Officer | President and CEO | 15 | 2016–2018 | |
| BARRIS PETER J | TenPercentOwner | 3 | 2017–2018 | ||
| BASKETT FOREST | TenPercentOwner | 3 | 2017–2018 | ||
| Florence Anthony A. Jr. | TenPercentOwner | 3 | 2017–2018 | ||
| Growth Equity Opportunities IV, LLC | TenPercentOwner | 3 | 2017–2018 | ||
| MAKOWER JOSHUA | TenPercentOwner | 3 | 2017–2018 | ||
| MOTT DAVID M | TenPercentOwner | 3 | 2017–2018 | ||
| NEA 15 GP, LLC | TenPercentOwner | 3 | 2017–2018 | ||
| NEA Partners 15, L.P. | TenPercentOwner | 3 | 2017–2018 | ||
| New Enterprise Associates 15, L.P. | TenPercentOwner | 3 | 2017–2018 | ||
| Sakoda Jon | TenPercentOwner | 3 | 2017–2018 | ||
| SANDELL SCOTT D | TenPercentOwner | 3 | 2017–2018 | ||
| Sonsini Peter W. | TenPercentOwner | 3 | 2017–2018 | ||
| Viswanathan Ravi | TenPercentOwner | 3 | 2017–2018 | ||
| Walker Luke Nathaniel | Officer | SVP, Clinical Development | 6 | 2017–2018 | |
| Azelby Robert | Director | 4 | 2017–2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2014-08-15 | Oncothyreon Inc. | Biotechnology | $22,861,428 | $22,861,428 | 5 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CASCADIAN THERAPEUTICS, INC. | WA | State business registries | name and state |
| Plan sponsor | CASCADIAN THERAPEUTICS, INC. | WA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Oncothyreon Inc. | WA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Cascadian Therapeutics, Inc. | WA | Patents (USPTO) | name and state |
| SEC filer | Cascadian Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | CASCADIAN THERAPEUTICS, INC. | WA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CASCADIAN THERAPEUTICS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Services-Commercial Physical & Biological Research, WA first:
- ROSETTA INPHARMATICS INC WA
- Absci Corp WA
- WEED, INC. AZ
- GLYCOTEX, INC. C3
- COMBICHEM INC CA
- AURORA BIOSCIENCES CORP CA
- SIGNAL PHARMACEUTICALS INC CA
- DELTAGEN INC CA
- MAXYGEN INC CA
- KOSAN BIOSCIENCES INC CA
In other datasets, the same topic (Medical research) in WA:
- Form D issuer: AbSci Corp (Form D private offerings)
- Nonprofit: ACCESS ABILITIES UNLIMITED (Nonprofits (IRS Form 990))
Interests: Services-Commercial Physical & Biological Research · Medical research